News | January 01, 2008

Reactions to Gadolinium-Based Contrast Agents Rare

January 2, 2008 – Allergic-like reactions to gadolinium-containing contrast injections in adults and pediatric patients, under the age of 19, are rare, according to a study conducted by researchers at the University of Michigan Health Systems in Ann Arbor, MI,.
Studying 78,353 gadolinium-containing contrast injections over five years, acute allergic-like reactions occurred after 54 injections, 48 reactions involved adults and six occurred in pediatric patients. Seventy-four percent of these reactions were mild, 19 percent were moderate and seven percent were marked as severe.

"Despite recent concerns that have emerged about the gadolinium-based contrast agents and the development of nephrogenic systemic fibrosis in patients who have severe chronic kidney disease, our study supports the long-held belief that gadolinium based contrast agents can be used safely in both pediatric and adult patients with normal or with only mildly impaired renal function," said Dr. Richard Cohan, co-author of the study. "The risk of allergic-like reactions is exceedingly low (0.07 percent of administrations in our study), and no fatal reaction occurred at our institution in more than 78,000 intravenous administrations. Patients should feel reassured, based on our results, that the intravenous gadolinium-contrast agents included in our study are quite safe when administered to patients with ample renal function," he said.

For more information: http://www.arrs.org

Related Content

OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...
TriHealth in Cincinnati

TriHealth in Cincinnati.

Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018
The continuing search for advantages to improve workflow has radiology departments constantly searching for new...
Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018
News | Contrast Media | February 28, 2018
February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other...
Guerbet to Participate in French Interventional Radiology Conference
News | Contrast Media | October 10, 2017
Guerbet announced it will be taking part in the 65th edition of the Journées Francophones de Radiologie (JFR) that will...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Experience at 3 Sites Utilizing Syringe-Less Contrast Injectors
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
contrast media
Feature | Contrast Media Injectors | March 02, 2017 | By Jeff Zagoudis
With medical imaging use on the rise, contrast media use is expected to grow as well, according to a May 2016 report...
contrast media
News | Contrast Media | December 09, 2016
At the 2016 Annual Meeting of the Radiological Society of North America (RSNA 2016), Bracco Diagnostics Inc. showcased...
GlobalData, contrast media injectors market,
News | Contrast Media Injectors | May 03, 2016
The global market for contrast media injectors is set to increase from $830 million in 2015 to almost $1.8 billion by...
CTA, CT, contrast media injector, contrast injector, EmpowerCTA

Bracco's new EmpowerCTA+, designed for cardiac CT angiography exams.

Feature | Contrast Media Injectors | April 29, 2016 | Jeff Zagoudis
The biggest trend in contrast media injector technology today is one seen throughout all of healthcare — doing more...